Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context and Transition to Focused Inquiry

The legacy context of general health and science information has long provided foundational knowledge on medication safety and adverse effects. Within this framework, public awareness of bisphosphonate therapies, such as Fosamax, has been established through broad educational materials. This heritage now serves as a baseline for more focused inquiry. Transitioning from this general awareness, attention shifts to a specific clinical concern: the potential association between Fosamax exposure and osteonecrosis of the jaw. This pivot moves from abstract health literacy toward a concrete risk assessment scenario. In occupational settings, particularly within dental and surgical practices, professionals encounter patients with histories of bisphosphonate use. The clinical evidence review of Fosamax and osteonecrosis of the jaw causation becomes a practical necessity. Practitioners must evaluate exposure history, duration of therapy, and procedural risks without relying on mechanistic speculation. This transition reframes general health knowledge into actionable occupational vigilance, emphasizing evidence-based review over theoretical claims. The focus remains on clinical observation and risk communication, aligning with the neutral academic tone required for professional discourse.

Pharmacology and Mechanism of Fosamax

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). This condition involves necrotic, exposed bone in the maxillofacial region that can occur spontaneously or following dental procedures. The clinical presentation of ONJ typically includes delayed healing after tooth extraction, local infection, and exposed bone that may persist for weeks to months. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes of jawbone pathology. The multiscale characterization of jawbone tissue has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The pharmacology of Fosamax involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for increasing bone mineral density, it can also impair the normal remodeling and repair processes in the jawbone. The jawbone has a high rate of turnover and is subject to microdamage from mastication, making it particularly vulnerable to the suppressive effects of bisphosphonates. Mechanistic pathways linking Fosamax to ONJ include the accumulation of the drug in bone, suppression of osteoclast activity, and subsequent impairment of bone healing. This can lead to necrosis when the jawbone is stressed by dental procedures or infection. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Risk Factors and Clinical Evidence

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4, stating that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It notes that ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing. The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the warning does not specify a precise timeline for risk reduction after discontinuation, and the optimal duration of use for Fosamax has not been determined, with consideration for drug discontinuation after 3 to 5 years of use in low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This leaves some ambiguity for clinicians and patients regarding the management of long-term therapy.

Causation Considerations and Temporal Relationship

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link, as the condition improves with drug cessation and recurs with re-exposure. However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be fully captured in clinical trials. The timeline between exposure and documented harm can vary widely, from days to months, and may be influenced by individual risk factors such as dental procedures or comorbidities. For patients who develop ONJ while on Fosamax, the label advises discontinuation if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of exposure, and patients with known risk factors should be monitored closely. The label also recommends that healthcare providers consider the benefits and risks of continuing bisphosphonate therapy in patients who require invasive dental procedures. Overall, while the warnings provide important guidance, the rare and unpredictable nature of ONJ underscores the need for careful patient selection and monitoring during Fosamax therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the primary mechanism by which Fosamax may cause osteonecrosis of the jaw?

Fosamax inhibits osteoclast-mediated bone resorption, reducing bone turnover. This can impair normal remodeling and repair in the jawbone, which has high turnover and is subject to microdamage, potentially leading to necrosis especially after dental procedures or infection.

What are the known risk factors for developing ONJ while on Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How does the prescribing information address the risk of ONJ with Fosamax?

The label includes a warning (section 5.4) that ONJ has been reported in patients taking bisphosphonates, including Fosamax. It notes that ONJ can occur spontaneously but is often associated with tooth extraction or local infection with delayed healing, and advises that discontinuation may reduce risk for patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.